Uncategorized - June 3, 2014
Sweden invests in research in Södertälje
On June 2 the Swedish Minister for Education, Jan Björklund, presented a new drive for research and education in Södertälje, south of Stockholm. With a mutual investment, the Swedish government – through KTH, the Royal Institute of Technology, the municipality of Södertälje – and AstraZeneca and Scania, the aim is to create a base of competence […]
Clinical Trials - May 12, 2014
Amgen and AstraZeneca announce positive results from psoriasis study
The two companies have announced positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis. According to AstraZeneca, the study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75 percent improvement from baseline […]
Clinical Trials - May 9, 2014
AstraZeneca starts phase III immunotherapy study
The study is a a phase III programme for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer (NSCLC) and other cancers. MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, […]
Collaboration - March 31, 2014
AstraZeneca and MRC enter collaboration
AstraZeneca and the Medical Research Council (MRC) have entered into a collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK. The AstraZeneca MRC UK Centre for Lead Discovery will sit within the new AstraZeneca […]
Acquisition - March 26, 2014
AstraZeneca completes Japanese acquisition
AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K. The company announced on March 26 that it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. According to a statement the purchase was valued at approximately JPY10 billion ($102 million). This gives AstraZeneca control of the entire shareholding of AstraZeneca K.K. “Our […]
Drug Development Pharma - March 12, 2014
AstraZeneca sells Alderley Park site in Cheshire
AstraZeneca is selling its Alderley Park site in Cheshire, UK, to Manchester Science Parks. Manchester Science Parks (MSP) is a Manchester-based public-private partnership and science park operator. Chris Oglesby, Chairman of MSP and Chief Executive of MSP majority shareholder, Bruntwood, commented in a statement: “We are delighted to have been entrusted with securing the future of Alderley […]
